Krilogy Financial LLC Cuts Holdings in Insulet Co. (NASDAQ:PODD)

Krilogy Financial LLC decreased its position in shares of Insulet Co. (NASDAQ:PODDGet Rating) by 10.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,329 shares of the medical instruments supplier’s stock after selling 271 shares during the period. Krilogy Financial LLC’s holdings in Insulet were worth $508,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PODD. Capital Research Global Investors lifted its stake in Insulet by 8.0% in the fourth quarter. Capital Research Global Investors now owns 7,811,512 shares of the medical instruments supplier’s stock worth $2,078,434,000 after purchasing an additional 579,764 shares during the last quarter. Marshall Wace LLP purchased a new position in Insulet in the fourth quarter worth $140,781,000. William Blair Investment Management LLC purchased a new stake in shares of Insulet during the first quarter valued at $136,901,000. Clearbridge Investments LLC grew its holdings in shares of Insulet by 38.8% during the first quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock valued at $452,016,000 after buying an additional 474,545 shares during the last quarter. Finally, D1 Capital Partners L.P. lifted its position in Insulet by 27.9% during the fourth quarter. D1 Capital Partners L.P. now owns 1,692,857 shares of the medical instruments supplier’s stock valued at $450,418,000 after purchasing an additional 368,775 shares during the period.

Insiders Place Their Bets

In related news, EVP Bret Christensen sold 2,900 shares of the business’s stock in a transaction that occurred on Wednesday, August 24th. The stock was sold at an average price of $264.24, for a total value of $766,296.00. Following the completion of the transaction, the executive vice president now directly owns 19,551 shares in the company, valued at approximately $5,166,156.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Insulet news, Director Shacey Petrovic sold 15,000 shares of the stock in a transaction on Friday, July 1st. The stock was sold at an average price of $222.90, for a total transaction of $3,343,500.00. Following the transaction, the director now owns 13,695 shares in the company, valued at approximately $3,052,615.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Bret Christensen sold 2,900 shares of the firm’s stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $264.24, for a total value of $766,296.00. Following the completion of the transaction, the executive vice president now owns 19,551 shares in the company, valued at approximately $5,166,156.24. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Robert W. Baird upped their price objective on shares of Insulet from $245.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, August 5th. Canaccord Genuity Group upped their price objective on shares of Insulet from $250.00 to $290.00 and gave the stock a “buy” rating in a report on Friday, August 5th. BTIG Research increased their target price on shares of Insulet to $285.00 in a report on Tuesday, August 9th. Morgan Stanley raised their price objective on shares of Insulet from $244.00 to $273.00 and gave the company an “equal weight” rating in a report on Monday, August 8th. Finally, Citigroup increased their target price on shares of Insulet to $260.00 in a research report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and an average price target of $295.23.

Insulet Trading Down 3.7 %

Shares of PODD stock opened at $241.25 on Friday. Insulet Co. has a 12 month low of $181.00 and a 12 month high of $324.81. The company has a quick ratio of 3.54, a current ratio of 4.69 and a debt-to-equity ratio of 3.28. The business’s 50 day moving average is $256.45 and its two-hundred day moving average is $240.24. The company has a market cap of $16.74 billion, a PE ratio of 482.50 and a beta of 0.73.

Insulet (NASDAQ:PODDGet Rating) last issued its earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.27). The firm had revenue of $299.40 million during the quarter, compared to the consensus estimate of $290.87 million. Insulet had a return on equity of 13.83% and a net margin of 2.94%. The firm’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period last year, the business earned $0.10 earnings per share. Equities analysts predict that Insulet Co. will post 0.76 EPS for the current year.

Insulet Company Profile

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Featured Articles

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDGet Rating).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.